Gary D Lewis1, Waqar Haque2, Andrew Farach2, Sandra S Hatch3, E Brian Butler2, Polly A Niravath4, Mary R Schwartz5, Elizabeth Bonefas6, Bin S Teh2. 1. Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States. 2. Department of Radiation Oncology, Houston Methodist Hospital, Houston, Texas, United States. 3. Department of Radiation Oncology, University of Texas Medical Branch, Galveston, Texas, United States. 4. Department of Clinical Medicine in Oncology, Houston Methodist Hospital, Houston, Texas, United States. 5. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, United States. 6. Breast Health Houston, Houston, Texas, United States.
Abstract
BACKGROUND: In invasive breast cancer, HER2 is a well-established negative prognostic factor. However, its significance on the prognosis of ductal carcinoma in situ (DCIS) of the breast is unclear. As a result, the impact of HER2-directed therapy on HER2-positive DCIS is unknown and is currently the subject of ongoing clinical trials. In this study, we aim to determine the possible impact of HER 2-directed targeted therapy on survival outcomes for HER2-positive DCIS patients. MATERIALS AND METHODS: The National Cancer Data Base (NCDB) was used to retrieve patients with biopsy-proven DCIS diagnosed from 2004-2015. Patients were divided into two groups based on the adjuvant therapy they received: systemic HER2-directed targeted therapy or no systemic therapy. Statistics included multivariable logistic regression to determine factors predictive of receiving systemic therapy, Kaplan-Meier analysis to evaluate overall survival (OS), and Cox proportional hazards modeling to determine variables associated with OS. RESULTS: Altogether, 1927 patients met inclusion criteria; 430 (22.3%) received HER2-directed targeted therapy; 1497 (77.7%) did not. Patients who received HER2-directed targeted therapy had a higher 5-year OS compared to patients that did not (97.7% vs. 95.8%, p = 0.043). This survival benefit remained on multivariable analysis. Factors associated with worse OS on multivariable analysis included Charlson-Deyo Comorbidity Score ≥ 2 and no receipt of hormonal therapy. CONCLUSION: In this large study evaluating HER2-positive DCIS patients, the receipt of HER2-directed targeted therapy was associated with an improvement in OS. The results of currently ongoing clinical trials are needed to confirm this finding.
BACKGROUND: In invasive breast cancer, HER2 is a well-established negative prognostic factor. However, its significance on the prognosis of ductal carcinoma in situ (DCIS) of the breast is unclear. As a result, the impact of HER2-directed therapy on HER2-positive DCIS is unknown and is currently the subject of ongoing clinical trials. In this study, we aim to determine the possible impact of HER 2-directed targeted therapy on survival outcomes for HER2-positive DCIS patients. MATERIALS AND METHODS: The National Cancer Data Base (NCDB) was used to retrieve patients with biopsy-proven DCIS diagnosed from 2004-2015. Patients were divided into two groups based on the adjuvant therapy they received: systemic HER2-directed targeted therapy or no systemic therapy. Statistics included multivariable logistic regression to determine factors predictive of receiving systemic therapy, Kaplan-Meier analysis to evaluate overall survival (OS), and Cox proportional hazards modeling to determine variables associated with OS. RESULTS: Altogether, 1927 patients met inclusion criteria; 430 (22.3%) received HER2-directed targeted therapy; 1497 (77.7%) did not. Patients who received HER2-directed targeted therapy had a higher 5-year OS compared to patients that did not (97.7% vs. 95.8%, p = 0.043). This survival benefit remained on multivariable analysis. Factors associated with worse OS on multivariable analysis included Charlson-Deyo Comorbidity Score ≥ 2 and no receipt of hormonal therapy. CONCLUSION: In this large study evaluating HER2-positive DCIS patients, the receipt of HER2-directed targeted therapy was associated with an improvement in OS. The results of currently ongoing clinical trials are needed to confirm this finding.
Authors: D Craig Allred; Stewart J Anderson; Soonmyung Paik; D Lawrence Wickerham; Iris D Nagtegaal; Sandra M Swain; Elefetherios P Mamounas; Thomas B Julian; Charles E Geyer; Joseph P Costantino; Stephanie R Land; Norman Wolmark Journal: J Clin Oncol Date: 2012-03-05 Impact factor: 44.544
Authors: Sahar Aly Daoud; Wesam Maghawri Ismail; Mohamed Salah Abdelhamid; Tamer Mohamed Nabil; Sahar Aly Daoud Journal: Asian Pac J Cancer Prev Date: 2016
Authors: Gary D Lewis; Yan Xing; Waqar Haque; Tejal Patel; Mary R Schwartz; Albert C Chen; Andrew Farach; Sandra S Hatch; E Brian Butler; Jenny C Chang; Bin S Teh Journal: Breast J Date: 2019-07-18 Impact factor: 2.431
Authors: Allison W Kurian; Rebecca Newton Thompson; Allison F Gaw; Sally Arai; Rafael Ortiz; Alan M Garber Journal: J Clin Oncol Date: 2007-02-20 Impact factor: 44.544
Authors: K E Williams; N L P Barnes; A Cramer; R Johnson; K Cheema; J Morris; M Howe; N J Bundred Journal: Ann Oncol Date: 2015-02-12 Impact factor: 32.976
Authors: Antonio C Wolff; M Elizabeth Hale Hammond; Kimberly H Allison; Brittany E Harvey; Pamela B Mangu; John M S Bartlett; Michael Bilous; Ian O Ellis; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Lisa M McShane; Mitchell Dowsett Journal: Arch Pathol Lab Med Date: 2018-05-30 Impact factor: 5.686
Authors: Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes Journal: Arch Pathol Lab Med Date: 2013-10-07 Impact factor: 5.534